UCONN Health Dermatology
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grimes, Fellicia
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
Lipson, Sherry
EMBARQ-CSU1, NCT06445023: A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Recruiting
3
915
Europe, US, RoW
barzolvolimab, Matching placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
10/26
04/27
NCT03747458: OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Recruiting
3
120
US
OPN-375
Optinose US Inc.
Bilateral Nasal Polyposis
03/26
03/26
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Active, not recruiting
2
208
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
09/23
03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting
2
196
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Chronic Inducible Urticaria
06/24
09/25
Utter, Lauren
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25

Download Options